BACKGROUND: Cancer patients with COVID-19 have a poor disease course. Among tumor types, prostate cancer and COVID-19 share several risk factors, and the interaction of prostate cancer and COVID-19 is purported to have an adverse outcome. METHODS: This was a single-institution retrospective study on 286,609 patients who underwent the COVID-19 test at Mount Sinai Hospital system from March 2020 to December 2020. Chi-square/Fisher's exact tests were used to summarize baseline characteristics of categorical data, and Mann-Whitney U test was used for continuous variables. Univariable logistic regression analysis to compare the hospitalization and mortality rates and the strength of association was obtained by the odds ratio and confidence interval. RESULTS: This study aimed to compare hospitalization and mortality rates between men with COVID-19 and prostate cancer and those who were COVID-19-positive with non-prostate genitourinary malignancy or any solid cancer, and with breast cancer patients. We also compared our studies to others that reported the incidence and severity of COVID-19 in prostate cancer patients. Our studies highlight that patients with prostate cancer had higher susceptibility to COVID-19-related pathogenesis, resulting in higher mortality and hospitalization rates. Hospitalization and mortality rates were higher in prostate cancer patients with COVID-19 when compared with COVID-19 patients with non-prostate genitourinary (GU) malignancies.
BACKGROUND:Cancerpatients with COVID-19 have a poor disease course. Among tumor types, prostate cancer and COVID-19 share several risk factors, and the interaction of prostate cancer and COVID-19 is purported to have an adverse outcome. METHODS: This was a single-institution retrospective study on 286,609 patients who underwent the COVID-19 test at Mount Sinai Hospital system from March 2020 to December 2020. Chi-square/Fisher's exact tests were used to summarize baseline characteristics of categorical data, and Mann-Whitney U test was used for continuous variables. Univariable logistic regression analysis to compare the hospitalization and mortality rates and the strength of association was obtained by the odds ratio and confidence interval. RESULTS: This study aimed to compare hospitalization and mortality rates between men with COVID-19 and prostate cancer and those who were COVID-19-positive with non-prostate genitourinary malignancy or any solid cancer, and with breast cancerpatients. We also compared our studies to others that reported the incidence and severity of COVID-19 in prostate cancerpatients. Our studies highlight that patients with prostate cancer had higher susceptibility to COVID-19-related pathogenesis, resulting in higher mortality and hospitalization rates. Hospitalization and mortality rates were higher in prostate cancerpatients with COVID-19 when compared with COVID-19patients with non-prostate genitourinary (GU) malignancies.
Entities:
Keywords:
COVID-19; hospitalization; mortality; prostate cancer
Authors: Markus Joerger; Yannis Metaxas; Khalil Zaman; Olivier Michielin; Nicolas Mach; Adrienne Bettini; Andreas M Schmitt; Nathan Cantoni; Clemens B Caspar; Sonja Stettler; Roma Malval; Miklos Pless; Christian Britschgi; Christoph Renner; Dieter Koeberle; Jessica D Schulz; Christoph Kopp; Stefanie Hayoz; Anastasios Stathis; Roger von Moos Journal: Cancers (Basel) Date: 2022-04-27 Impact factor: 6.575
Authors: Jim Q Ho; Mohammad Reza Sepand; Banafsheh Bigdelou; Tala Shekarian; Rahim Esfandyarpour; Prashant Chauhan; Vahid Serpooshan; Lalit K Beura; Gregor Hutter; Steven Zanganeh Journal: Immunology Date: 2022-05-03 Impact factor: 7.215
Authors: Adana A M Llanos; Angela J Fong; Nabarun Ghosh; Katie A Devine; Denalee O'Malley; Lisa E Paddock; Elisa V Bandera; Shawna V Hudson; Andrew M Evens; Sharon L Manne Journal: J Cancer Surviv Date: 2022-07-29 Impact factor: 4.062
Authors: Darren M C Poon; Kuen Chan; Tim Chan; Foo-Yiu Cheung; Daisy Lam; Martin Lam; Ka-Suet Law; Conrad Lee; Eric K C Lee; Angus Leung; Henry Sze; Chi-Chung Tong; Kenneth C W Wong; Philip Kwong Journal: Cancers (Basel) Date: 2022-01-14 Impact factor: 6.639